The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

▎药明康德内容团队编辑日前，辉瑞（Pfizer）宣布美国FDA已批准其呼吸道合胞病毒（RSV）疫苗Abrysvo（RSVpreF），用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病（LRTD）。此前，该疫苗已获批用于60岁及以上的成人群体。根 ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

近日，在洛杉矶举行的2024年美国感染性疾病周（IDWeek）会议期间，默沙东和辉瑞分别展示了其针对呼吸道合胞病毒（RSV）的预防药物新数据，并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会，每年吸引 ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...

辉瑞制药针对呼吸道合胞体病毒（RSV）的疫苗获得美国食品药品管理局（FDA）批准，用于18-59岁年龄段人群接种。